"Drug Resistance, Viral" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The ability of viruses to resist or to become tolerant to chemotherapeutic agents or antiviral agents. This resistance is acquired through gene mutation.
| Descriptor ID |
D024882
|
| MeSH Number(s) |
G06.225.420 G06.920.225 G07.690.773.984.269.420
|
| Concept/Terms |
Drug Resistance, Viral- Drug Resistance, Viral
- Drug Resistances, Viral
- Antiviral Drug Resistance
- Antiviral Drug Resistances
|
Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Viral".
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Viral".
This graph shows the total number of publications written about "Drug Resistance, Viral" by people in this website by year, and whether "Drug Resistance, Viral" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2003 | 2 | 2 | 4 |
| 2004 | 1 | 4 | 5 |
| 2005 | 2 | 1 | 3 |
| 2006 | 2 | 2 | 4 |
| 2007 | 3 | 1 | 4 |
| 2008 | 5 | 3 | 8 |
| 2009 | 3 | 1 | 4 |
| 2010 | 4 | 2 | 6 |
| 2011 | 2 | 3 | 5 |
| 2012 | 5 | 4 | 9 |
| 2013 | 2 | 3 | 5 |
| 2014 | 3 | 3 | 6 |
| 2015 | 1 | 2 | 3 |
| 2016 | 5 | 8 | 13 |
| 2017 | 64 | 67 | 131 |
| 2018 | 63 | 64 | 127 |
| 2019 | 31 | 23 | 54 |
| 2020 | 6 | 8 | 14 |
| 2021 | 2 | 12 | 14 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Resistance, Viral" by people in Profiles.
-
Evolution of viral variants in remdesivir-treated and untreated SARS-CoV-2-infected pediatrics patients. J Med Virol. 2022 01; 94(1):161-172.
-
Interface-based design of the favipiravir-binding site in SARS-CoV-2 RNA-dependent RNA polymerase reveals mutations conferring resistance to chain termination. FEBS Lett. 2021 09; 595(18):2366-2382.
-
Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2. Viruses. 2021 08 19; 13(8).
-
Shutting the gate before the horse has bolted: is it time for a conversation about SARS-CoV-2 and antiviral drug resistance? J Antimicrob Chemother. 2021 08 12; 76(9):2230-2233.
-
Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group. Antiviral Res. 2021 10; 194:105158.
-
Highlights from the 11th IAS Conference on Science. Lancet HIV. 2021 08; 8(8):e459.
-
HIV-1 genetic diversity and drug resistance mutations in the northern Brazilian region. Braz J Infect Dis. 2021 May-Jun; 25(3):101596.
-
Hypothesis of zinc ascorbate as best zinc ionophore for raising antiviral resistance against Covid-19. J Med Virol. 2021 09; 93(9):5205-5208.
-
Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors. Indian J Pharmacol. 2021 May-Jun; 53(3):226-228.
-
Nanoparticle composite TPNT1 is effective against SARS-CoV-2 and influenza viruses. Sci Rep. 2021 04 22; 11(1):8692.